Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
2024年7月30日 - 12:00AM
Press release – 7 / 2024
Zealand Pharma Appoints Eric Cox as Chief Commercial
Officer
Copenhagen, Denmark, 29 July 2024
– Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.
20045078), a biotechnology company focused on the discovery and
development of innovative peptide-based medicines, today announced
the appointment of Eric Cox as Zealand’s Chief Commercial Officer
starting August 5, 2024. Eric will join the executive team to lead
Zealand’s commercial strategy and assume responsibility for
business development.
Eric brings 25 years of commercial experience from biotech and
leading global biopharma companies that includes pre-commercial
planning, product and portfolio strategy, business development, and
launch strategy. Most recently, Eric was at Carmot Therapeutics (a
member of the Roche Group), where he led commercial strategy and
business development for the obesity and metabolism franchise.
Previously, he was the U.S. commercial franchise leader for
diabetes, heart failure, and chronic kidney disease at AstraZeneca.
Before AstraZeneca, Eric spent more than 15 years at Merck, where
he was the global franchise leader (marketing) for the
cardiovascular and rare disease franchise, leading global and
regional teams responsible for pipeline and in-line commercial
strategy for marketed and pre-commercial assets. While at Merck,
Eric co-led a product development team to develop clinical trial
designs for products throughout the lifecycle and held leadership
marketing positions for large markets including the contraceptive
franchise, atherothrombosis and the U.S. cholesterol franchise. He
has also held marketing positions of increasing responsibility at
Bayer, Johnson & Johnson, and TAP Pharmaceuticals. Eric
received an M.B.A. in marketing and finance from Missouri State
University and a B.A. from the University of Kansas.
“We are delighted to welcome Eric to Zealand as our Chief
Commercial Officer,” said Adam Steensberg, Chief Executive Officer,
Zealand Pharma. “Eric’s experience and track record further
strengthen our team as we explore co-development and co-commercial
opportunities for our differentiated obesity assets advancing into
comprehensive Phase 2b trials and our rare disease programs
approaching regulatory decisions.”
“I am excited to be joining Zealand Pharma with its robust
pipeline of next generation obesity candidates,” said Eric Cox. “I
look forward to working with the team as Zealand seeks to play a
key role in shaping the evolving market for weight management with
next generation product candidates.”
About Zealand Pharma A/S
Zealand Pharma A/S is a biotechnology company focused on the
discovery and development of peptide-based medicines. More than 10
drug candidates invented by Zealand have advanced into clinical
development, of which two have reached the market and three
candidates are in late-stage development. The Company has
development partnerships with several pharma companies as well as
commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen,
Denmark, with a presence in the U.S. For more information about
Zealand’s business and activities, please visit
www.zealandpharma.com.
Forward looking statements
This press release contains “forward-looking statements”, as
that term is defined in the Private Securities Litigation Reform
Act of 1995 in the United States, as amended, even though no longer
listed in the United States this is used as a definition to provide
Zealand Pharma’s expectations or forecasts of future events
regarding the research, development and commercialization of
pharmaceutical products, the timing of the company’s pre-clinical
and clinical trials and the reporting of data therefrom. These
forward-looking statements may be identified by words such as
“aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,”
“forecast,” “goal,” “intend,” “may,” “plan,” “possible,”
“potential,” “will,” “would” and other words and terms of similar
meaning. You should not place undue reliance on these statements,
or the scientific data presented. The reader is cautioned not to
rely on these forward-looking statements. Such forward-looking
statements are subject to risks, uncertainties and inaccurate
assumptions, which may cause actual results to differ materially
from expectations set forth herein and may cause any or all of such
forward-looking statements to be incorrect, and which include, but
are not limited to, unexpected costs or delays in clinical trials
and other development activities due to adverse safety events,
patient recruitment or otherwise; unexpected concerns that may
arise from additional data, analysis or results obtained during
clinical trials; our ability to successfully market both new and
existing products; changes in reimbursement rules and governmental
laws and related interpretation thereof; government-mandated or
market-driven price decreases for our products; introduction of
competing products; production problems at third party
manufacturers; dependency on third parties, for instance contract
research or development organizations; unexpected growth in costs
and expenses; our ability to effect the strategic reorganization of
our businesses in the manner planned; failure to protect and
enforce our data, intellectual property and other proprietary
rights and uncertainties relating to intellectual property claims
and challenges; regulatory authorities may require additional
information or further studies, or may reject, fail to approve or
may delay approval of our drug candidates or expansion of product
labeling; failure to obtain regulatory approvals in other
jurisdictions; exposure to product liability and other claims;
interest rate and currency exchange rate fluctuations; unexpected
contract breaches or terminations; inflationary pressures on the
global economy; and political uncertainty, including the ongoing
military conflict in Ukraine and the uncertainty surrounding
upcoming elections in the US. If any or all of such forward-looking
statements prove to be incorrect, our actual results could differ
materially and adversely from those anticipated or implied by such
statements. The foregoing sets forth many, but not all, of the
factors that could cause actual results to differ from our
expectations in any forward-looking statement. All such
forward-looking statements speak only as of the date of this
company announcement and are based on information available to
Zealand Pharma as of the date of this announcement. We do not
undertake to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof.
Information concerning pharmaceuticals (including compounds under
development) contained within this material is not intended as
advertising or medical advice.
Contact:
Adam LangeInvestor Relations OfficerZealand PharmaEmail:
akl@zealandpharma.com
Anna Krassowska, PhDVice President, Investor Relations &
Corporate CommunicationsZealand PharmaEmail:
ank@zealandpharma.com